<DOC>
	<DOCNO>NCT02391051</DOCNO>
	<brief_summary>This trial examine feasibility toxicity focal brachytherapy patient low-risk prostate cancer .</brief_summary>
	<brief_title>Focal Brachytherapy Patients With Selected `` Low-risk '' Prostate Cancer - Phase-II-trial</brief_title>
	<detailed_description>Patients low-risk prostate cancer receive HDR-Brachytherapy : 2 x 13,5 Gy .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Age &gt; 18 Histologically confirm prostate cancer Gleason Score index lesion ≤ 6 ( 3+3 ) Tumor stage : cT12a cN0 cM0 Unilateral affection ; index lesion ≤ 0.5ml without clinically nonsignificant lesion contralateral . No 25 % punch affect . Therefore 3DTPMbiopsy mandatory treatment . PSA ≤ 10/ng/ml Prostate volume &lt; 60 m^3 No distant metastasis Life expectancy &gt; 10 year Informed consent Tumor stage ≥ T2b Known metastasis : N+ and/or M1 General anesthesia peridural anesthesia possible Coagulation disorder</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>focal brachytherapy</keyword>
	<keyword>PSA</keyword>
	<keyword>Biological marker</keyword>
</DOC>